CLINICO-PHARMACOLOGICAL STUDY ON NY-198 IN OTORHINOLARYNGOLOGY

• Published in: CHEMOTHERAPY Vol. 36; no. Supplement2-Clinical; pp. 1303 - 1313
• Main Authors: HIRATA, TETSUYASU, SEKITANI, TORU
• Format: Journal Article
• Language: English; Japanese
• Published: Japanese Society of Chemotherapy 1988
• ISSN: 0009-3165; 1884-5894
• DOI: 10.11250/chemotherapy1953.36.Supplement2-Clinical_1303

We performed a clinico-pharmacological study on NY-198, with the following results. 1. The efficacy against otorhinolaryngological infections was evaluated in 49 cases as: excellent 11, good 21, fair 7, and poor 10. The total efficacy rate was 65.3%. The efficacy rate was 46.2% in otitis media (OM)(80% in acute OM, 25% in chronic OM, and 55.6% in exacerbation of chronic OM), 81.8% in paranasal sinusitis and 87.5% in tonsillitis. 2. Adverse reactions were observed in 4 of the 49 cases, including diarrhea in 2 and abdominal discomfort in 2. But these were mild and easily controlled. 3. Concentration of NY-198 in tissues was studied after oral administration of 200mg (2 capsules). Tissues consisting of nasal polyp, inferior turbinate, maxillary mucosa, and venous blood were collected for assaying. The concentration in nasal polyp and mucosa of the maxillary sinus was the same as or higher than in serum.